DHA regulates angiogenesis and improves the efficiency of CDDP for the treatment of lung carcinoma

Microvascular Research

Volumn 87, Issue , 2013, Pages 14-24

  Zhang, Jia Li ^a,c   Wang, Zeng ^a,b   Hu, Wei ^a   Chen, Sang Sang ^a   Lou, Xiao E ^a   Zhou, Hui Jun ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DIHYDROARTEMISININ; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG TUMOR LEVEL; HUMAN; HUMAN CELL; LUNG CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ARTEMISININS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SYNERGISM; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84876309462     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2013.02.006     Document Type: Article

References (37)

1. Airley R.E., Monaghan J.E., Stratford I.J. Hypoxia and disease: opportunities for novel diagnostic and therapeutic prodrug strategies. Pharm. J. 2000, 264:666-673.
2. Bagley R.G., Honma N., Weber W., et al. Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization. Microvasc. Res. 2008, 76:180-188.
3. Brouwers E.E., Tibben M.M., Pluim D., et al. Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin. Anal. Bioanal. Chem. 2008, 391:577-585.
4. Cerniglia G.J., Pore N., Tsai J.H., et al. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One 2009, 4:6539-6550.
5. Chen H.H., Zhou H.J., Fang X. Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol. Res. 2003, 48:231-236.
6. Chen H.H., Zhou H.J., Wu G.D., Lou X.E. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. Pharmacology 2004, 71:1-9.
7. Chen H., Sun B., Pan S.H., et al. Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anticancer Drugs 2009, 20:131-140.
8. Chou T.C., Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur. J. Biochem. 1981, 115:207-216.
9. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
10. Huang L.Eric, Bunn H.Franklin Hypoxia-inducible factor and its biomedical relevance. J. Biol. Chem. 2003, 278:19575-19578.
11. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1:27-31.
12. Fujita T., Felix K., Pinkaew D., et al. Human fortilin is a molecular target of dihydroartemisinin. FEBS Lett. 2008, 582:1055-1060.
13. Giordano F.J., Johnson R.S. Angiogenesis: the role of the microenvironment in flipping the switch. Curr. Opin. Genet. Dev. 2001, 11:35-40.
14. Guise T. Examining the metastatic niche: targeting the microenvironment. Semin. Oncol. 2010, 37:2-14.
15. Adrian L.Harris Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2:38-47.
16. Horimatsu T., Sano Y., Kaneko K., et al. Relationship between MVD and meshed-capillaries using magnifying NBI colonoscopy in colorectal precursor lesions. Hepatogastroenterology 2009, 56:372-377.
17. Hou J., Wang D., Zhang R., et al. Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin. Cancer Res. 2008, 14:5519-5530.
18. Jacquemier J., Mathoulin-Portier M.P., Valtola R., et al. Prognosis of breast-carcinoma lymphangiogenesis evaluated by immunohistochemical investigation of vascular-endothelial-growth-factor receptor 3. Int. J. Cancer 2000, 89:69-73.
19. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
20. Kallergi G., Markomanolaki H., Giannoukaraki V., et al. Hypoxia-inducible factor-1 alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res. 2009, 11:217-228.
21. Kang M.H., Kang Y.H., Szymanska B., et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 2007, 110:2057-2066.
22. Kern J., Steurer M., Gastl G., et al. Vasohibin inhibits angiogenic sprouting in vitro and supports vascular maturation processes in vivo. BMC Cancer 2009, 9:284-295.
23. Koshikawa N., Iyozumi A., Gassmann M., et al. Constitutive upregulation of hypoxia-inducible factor-1alpha mRNA occurring in highly metastatic lung carcinoma cells leads to vascular endothelial growth factor overexpression upon hypoxic exposure. Oncogene 2003, 22:6717-6724.
24. Lee E.O., Lee H.J., Hwang H.S., et al. Potent inhibition of Lewis lung cancer growth by heyneanol A from the roots of Vitis amurensis through apoptotic and anti-angiogenic activities. Carcinogenesis 2006, 27:2059-2069.
25. Li J., Zhou H.J. Dihydroartemisinin downregulates vascular endothelial growth factor expression and induces apoptosis in chronic myeloid leukemia K562 cells. Cancer Chemother. Pharmacol. 2006, 57:213-220.
26. Maynard M.A., ohh M. The role of hypoxia-inducible factors in cancer. Cell. Mol. Life Sci. 2007, 64:2170-2180.
27. Mu D., Zhang W., Chu D., et al. The role of calcium, P38 MAPK in dihydroartemisinin-induced apoptosis of lung cancer PC-14 cells. Cancer Chemother. Pharmacol. 2008, 61:639-645.
28. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
29. Pignon J.P., Tribodet H., Gi Scagliotti, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J. Clin. Oncol. 2008, 26:3552-3559.
30. Raspollini M.R., Amunni G., Villanucci A., et al. Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced serous carcinoma. Int. J. Gynecol. Cancer 2004, 14:815-823.
31. Schiller J., Harrington D., Belani C., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. Med. 2002, 346:92-98.
32. Solyanik G.I. Multifactorial nature of tumor drug resistance. Exp. Oncol. 2010, 32:181-185.
33. Sun X., Kanwar J.R., Leung E., et al. Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression. Cancer Gene Ther. 2001, 8:719-727.
34. Tang N., Wang L., Esko J., et al. Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004, 6:485-495.
35. Ugur Ozerdem M.D. Targeting pericytes diminishes neovascularization in orthotopic uveal melanoma in NG2 proteoglycan knockout mouse. Ophthalmic Res. 2006, 38:251-254.
36. Zhang F., Zhang T., Gu Z.P., et al. Enhancement of radiosensitivity by roscovitine pretreatment in human non-small cell lung cancer A549 cells. J. Radiat. Res. 2008, 49:541-548.
37. Zhou H.J., Zhang J.L., Li A., et al. Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro. Cancer Chemother. Pharmacol. 2010, 66:21-29.